Poster-Disease-modifying Therapy
October 25, 2021
Clinical Outcomes in Patients with COVID-19 Infection during Phase IV Studies of Cladribine Tablets for Treatment of Multiple Sclerosis
Background: The COVID-19 pandemic has become a significant concern for patients with multiple sclerosis (MS) and their healthcare...
Poster-Disease-modifying Therapy
October 25, 2021
Online Medical Education Increases Knowledge Among Neurologists of Safety Considerations for Disease Modifying Therapies in Multiple Sclerosis
Background: Disease modifying therapies (DMTs) have transformed the management of multiple sclerosis (MS). Patients can now live many years...
Poster-Disease-modifying Therapy
October 25, 2021
Adherence and Persistence to Injectable Disease-Modifying Therapies Among Patients with Multiple Sclerosis Enrolled in US Commercial Plans
Background: In patients with multiple sclerosis (MS), adherence and persistence to disease-modifying therapies (DMTs) are important to...
Poster-Disease-modifying Therapy
October 25, 2021
Evaluating Perceptions of Ofatumumab in Multiple Sclerosis Via Social Media Listening Early 3 Months Post Approval Data
Background: Superior efficacy and safety of ofatumumab were demonstrated in Phase III ASCLEPIOS trials. Objectives: The social media...
Poster-Disease-modifying Therapy
October 25, 2021
Olikos Study Design: Exploring Maintained Ofatumumab Efficacy in Relapsing MS Patients Who Transition from Intravenous Anti-CD20 Therapy
Background: B-cell depletion in patients with relapsing multiple sclerosis (RMS) using anti-CD20 monoclonal antibodies (mAbs) reduces...
Poster-Disease-modifying Therapy
October 25, 2021
Updated Post-Approval Safety of Cladribine Tablets in the Treatment of Multiple Sclerosis, with Particular Reference to Respiratory Viral Infections and COVID-19
Background: Several integrated analyses have reported on the safety of cladribine tablets 10 mg (3.5 mg/kg cumulative dose over 2 years...
Poster-Disease-modifying Therapy
October 25, 2021
Treatment Persistence, Safety, Tolerability, and Effectiveness of Diroximel Fumarate in the Real-World: Design of the Phase 4 ExperienceUS Study
Background: Diroximel fumarate (DRF) is an oral fumarate approved in the United States (US) for relapsing multiple sclerosis (MS). DRF...
Poster-Disease-modifying Therapy
October 25, 2021
Real World Experience with Systemic Injection Reactions to Ofatumumab
Background: Ofatumumab is a subcutaneously administered B cell depleting agent approved by the FDA for use in patients with relapsing forms...
Poster-Disease-modifying Therapy
October 25, 2021
COVID-19 Prevention Behaviors and PCR Testing Among MS Patients Treated with Different Dmts: Survey Data from MS Paths
Background: Emerging data from people with multiple sclerosis (PwMS) suggest that some disease-modifying therapies (DMTs) may impact the...
Poster-Disease-modifying Therapy
October 25, 2021
Efficacy and Safety of Eculizumab in Patients with Neuromyelitis Optica Spectrum Disorder Previously Treated with Rituximab: Findings from Prevent
Background: In PREVENT, eculizumab was associated with a significant reduction in relapse risk versus placebo and was well tolerated. In...